Silencing ARID1B impaired cellular proliferation in cancer cells with ARID1A mutations, but not in cells with wild-type ARID1A, suggesting that ARID1B is a potential therapeutic target for cancers with ARID1A mutation. Here, ARID1A is linked to cancer.